Revumenib
Overview of the drug Revumenib
| Revumenib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Revumenib is an investigational drug that acts as an inhibitor of the menin-MLL interaction, which is implicated in certain types of acute leukemia. It is being studied for its potential use in treating acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with specific genetic mutations.
Mechanism of Action[edit | edit source]
Revumenib functions by inhibiting the interaction between menin and mixed-lineage leukemia (MLL) proteins. This interaction is crucial for the proliferation of leukemia cells that harbor MLL rearrangements or NPM1 mutations. By disrupting this interaction, Revumenib aims to halt the growth of these cancerous cells and induce apoptosis.
Clinical Development[edit | edit source]
Revumenib is currently undergoing clinical trials to evaluate its safety and efficacy in patients with relapsed or refractory AML and ALL. These trials are particularly focused on patients with MLL rearrangements or NPM1 mutations, as these genetic alterations are known to drive the pathogenesis of these leukemias.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of Revumenib is characterized by its absorption, distribution, metabolism, and excretion properties. It is designed to be administered orally, allowing for convenient dosing in a clinical setting. The drug's metabolism and elimination pathways are being studied to optimize its therapeutic window and minimize potential side effects.
Potential Side Effects[edit | edit source]
As with many investigational drugs, Revumenib may have side effects. Commonly observed adverse effects in clinical trials include cytopenias, gastrointestinal disturbances, and fatigue. Ongoing studies aim to further elucidate the safety profile of Revumenib and manage any adverse reactions effectively.
Future Directions[edit | edit source]
The development of Revumenib represents a promising advance in the targeted treatment of leukemias with specific genetic profiles. Future research will focus on combination therapies, resistance mechanisms, and expanding the indications for Revumenib to include other hematological malignancies.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
